Scholarlink

<p>Cerebral malaria (CM) remains one of the most severe complications of <i>Plasmodium falciparum</i> infection, often leading to death within days and leaving survivors with lasting cognitive damage. Since current treatments target the parasite but offer little to no neuroprotection, we explored whether existing neuroprotective drugs could help fill this gap. Six clinically-approved drugs, viz. topiramate, rasagiline, vinpocetine, cilostazol, piracetam, and rivastigmine were tested for both antimalarial and anti-cerebral malaria activity. Screening against <i>P. falciparum</i> in vitro showed that vinpocetine, cilostazol, and rivastigmine effectively inhibited parasite growth, without causing toxicity in Vero or BB19 cell lines or in human red blood cells. In a mouse model of experimental CM (<i>Plasmodium berghei</i> ANKA-infected C57BL/6 mice), early oral treatment with cilostazol, piracetam, or rivastigmine delayed the onset of CM symptoms and significantly improved survival compared to untreated controls. When treatment was initiated after the first neurological signs, only the combination of rivastigmine with the fast-acting antimalarial α/β-arteether markedly improved outcomes, including parasite clearance and extended survival, compared to either treatment alone. Overall, these results suggest that combining rivastigmine with α/β-arteether may represent a practical and low-cost adjunct therapy for CM. Further mechanistic and clinical studies will be essential to confirm these findings and assess long-term outcomes.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluation of clinically approved neuroprotective drugs as adjunct therapies in experimental cerebral malaria

  • 期刊论文

  • 发表日期：

    2026年2月3日

查看全文
  • Prince Joshi,
  • Salique Hassan Shaham,
  • Rahul Shivahare,
  • Kanchan Yadav,
  • Anamika Sharma,
  • Parul,
  • Shubha Shukla,
  • Renu Tripathi

摘要

Cerebral malaria (CM) remains one of the most severe complications of Plasmodium falciparum infection, often leading to death within days and leaving survivors with lasting cognitive damage. Since current treatments target the parasite but offer little to no neuroprotection, we explored whether existing neuroprotective drugs could help fill this gap. Six clinically-approved drugs, viz. topiramate, rasagiline, vinpocetine, cilostazol, piracetam, and rivastigmine were tested for both antimalarial and anti-cerebral malaria activity. Screening against P. falciparum in vitro showed that vinpocetine, cilostazol, and rivastigmine effectively inhibited parasite growth, without causing toxicity in Vero or BB19 cell lines or in human red blood cells. In a mouse model of experimental CM (Plasmodium berghei ANKA-infected C57BL/6 mice), early oral treatment with cilostazol, piracetam, or rivastigmine delayed the onset of CM symptoms and significantly improved survival compared to untreated controls. When treatment was initiated after the first neurological signs, only the combination of rivastigmine with the fast-acting antimalarial α/β-arteether markedly improved outcomes, including parasite clearance and extended survival, compared to either treatment alone. Overall, these results suggest that combining rivastigmine with α/β-arteether may represent a practical and low-cost adjunct therapy for CM. Further mechanistic and clinical studies will be essential to confirm these findings and assess long-term outcomes.

Graphical abstract